Literature DB >> 27635933

Liver Capsule: FXR agonists against liver disease.

Claudia D Fuchs1, Philipp Schwabl1, Thomas Reiberger1, Michael Trauner2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27635933      PMCID： PMC5091632          DOI： 10.1002/hep.28836

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
apical sodium‐dependent bile acid transporter bile acid bile salt export pump cancer antigen chenodeoxycholic acid cholesterol cyclooxygenase 2 endothelial NO synthase endothelin 1 fatty acid free fatty acid fibroblast growth factor FGF receptor farnesoid X receptor hepatocellular carcinoma high‐density lipoprotein interferon insulin‐like growth factor 1 receptor interleukin inducible NO synthase Kupffer cell low‐density lipoprotein LDL receptor liver sinusoidal endothelial cell monocyte chemoattractant protein 1 multidrug resistance matrix metalloproteinase nonalcoholic fatty liver disease nonalcoholic steatohepatitis nuclear factor kappa B nitric oxide sodium/taurocholate cotransporting polypeptide phospholipids scavenger receptor class B type 1 phosphorylated signal transducer and activator of transcription 3 triglyceride transforming growth factor tissue inhibitor of metalloproteinase tight junction tumor necrosis factor vascular cell adhesion molecule very low‐density lipoprotein zona occludens 1.
  5 in total

1.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Authors:  Brent A Neuschwander-Tetri; Rohit Loomba; Arun J Sanyal; Joel E Lavine; Mark L Van Natta; Manal F Abdelmalek; Naga Chalasani; Srinivasan Dasarathy; Anna Mae Diehl; Bilal Hameed; Kris V Kowdley; Arthur McCullough; Norah Terrault; Jeanne M Clark; James Tonascia; Elizabeth M Brunt; David E Kleiner; Edward Doo
Journal:  Lancet       Date:  2014-11-07       Impact factor: 79.321

2.  Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.

Authors:  Len Verbeke; Ricard Farre; Jonel Trebicka; Mina Komuta; Tania Roskams; Sabine Klein; Ingrid Vander Elst; Petra Windmolders; Tim Vanuytsel; Frederik Nevens; Wim Laleman
Journal:  Hepatology       Date:  2014-04-14       Impact factor: 17.425

3.  Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor.

Authors:  Takeshi Inagaki; Antonio Moschetta; Youn-Kyoung Lee; Li Peng; Guixiang Zhao; Michael Downes; Ruth T Yu; John M Shelton; James A Richardson; Joyce J Repa; David J Mangelsdorf; Steven A Kliewer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-10       Impact factor: 11.205

4.  Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output.

Authors:  Anna Baghdasaryan; Thierry Claudel; Judith Gumhold; Dagmar Silbert; Luciano Adorini; Aldo Roda; Stefania Vecchiotti; Frank J Gonzalez; Kristina Schoonjans; Mario Strazzabosco; Peter Fickert; Michael Trauner
Journal:  Hepatology       Date:  2011-10       Impact factor: 17.425

5.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

Authors:  Frederik Nevens; Pietro Andreone; Giuseppe Mazzella; Simone I Strasser; Christopher Bowlus; Pietro Invernizzi; Joost P H Drenth; Paul J Pockros; Jaroslaw Regula; Ulrich Beuers; Michael Trauner; David E Jones; Annarosa Floreani; Simon Hohenester; Velimir Luketic; Mitchell Shiffman; Karel J van Erpecum; Victor Vargas; Catherine Vincent; Gideon M Hirschfield; Hemant Shah; Bettina Hansen; Keith D Lindor; Hanns-Ulrich Marschall; Kris V Kowdley; Roya Hooshmand-Rad; Tonya Marmon; Shawn Sheeron; Richard Pencek; Leigh MacConell; Mark Pruzanski; David Shapiro
Journal:  N Engl J Med       Date:  2016-08-18       Impact factor: 91.245
  5 in total
  5 in total

Review 1.  The Crosstalk Between Liver Sinusoidal Endothelial Cells and Hepatic Microenvironment in NASH Related Liver Fibrosis.

Authors:  Wei Du; Lin Wang
Journal:  Front Immunol       Date:  2022-06-28       Impact factor: 8.786

2.  Novel treatment options for portal hypertension.

Authors:  Philipp Schwabl; Wim Laleman
Journal:  Gastroenterol Rep (Oxf)       Date:  2017-04-18

3.  SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.

Authors:  Jiyu Zhou; Shuang Cui; Qingxian He; Yitong Guo; Xiaojie Pan; Pengfei Zhang; Ningning Huang; Chaoliang Ge; Guangji Wang; Frank J Gonzalez; Hong Wang; Haiping Hao
Journal:  Nat Commun       Date:  2020-01-13       Impact factor: 14.919

4.  The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model.

Authors:  Philipp Schwabl; Eva Hambruch; Grant R Budas; Paul Supper; Michael Burnet; John T Liles; Manfred Birkel; Ksenia Brusilovskaya; Philipp Königshofer; Markus Peck-Radosavljevic; William J Watkins; Michael Trauner; David G Breckenridge; Claus Kremoser; Thomas Reiberger
Journal:  Biomedicines       Date:  2021-01-09

Review 5.  Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.

Authors:  Margery A Connelly; Jonathan Velez Rivera; John R Guyton; Mohammad Shadab Siddiqui; Arun J Sanyal
Journal:  Aliment Pharmacol Ther       Date:  2020-07-08       Impact factor: 9.524
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.